Clinical Trial Detail

NCT ID NCT02569242
Title Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Ono Pharmaceutical Co. Ltd
Indications

esophageal cancer

Therapies

Docetaxel + Paclitaxel

Nivolumab

Age Groups: adult senior

No variant requirements are available.